Gyeongnam Pharmaceutical Decides on 38 Billion KRW Paid-in Capital Increase
[Asia Economy Reporter Lee Gwan-ju] Kyungnam Pharmaceutical announced on the 24th that it has decided to conduct a paid-in capital increase through a rights offering followed by a general public offering of unsubscribed shares to raise approximately 38 billion KRW for facility and operating funds as well as debt repayment funds. The new shares consist of 10.8 million common shares, with a planned issue price of 3,650 KRW per share.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- NVIDIA Reports $81.6 Billion in Q1 Revenue, Sets Record for 12 Consecutive Quarters (Comprehensive)
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
